
Moderna (MRNA) Stock Forecast & Price Target
Moderna (MRNA) Analyst Ratings
Bulls say
Moderna's stock outlook remains positive due to its expanding portfolio, which includes 40 mRNA candidates across various therapeutic areas like oncology and infectious diseases, indicating strong growth potential. The company's valuation of key developmental candidates, such as mRNA-4157, has risen to $2.79 billion, showcasing confidence in its future revenue streams from innovative therapies. Additionally, Moderna's commitment to preventive vaccines and alignment with ESG principles supports a sustainable growth model, further enhancing its overall financial stability and resilience in the biotech sector.
Bears say
Moderna has reported a significant decline in COVID vaccine sales, with revenues dropping from $18 billion in 2022 to $6.7 billion in 2023, prompting a downward revision of guidance for 2024 due to anticipated market headwinds. The company's valuation of its key products, including Spikevax, has also decreased sharply, reflecting reduced expectations for long-term COVID-related sales, which are now projected to fall further as the pandemic transitions to an endemic phase. Overall, the firm's financial outlook is clouded by uncertainties regarding vaccination rates and limited contributions from other vaccine candidates, leading to expectations of flat or declining top-line revenue through 2025.
This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.
Moderna (MRNA) Analyst Forecast & Price Prediction
Start investing in Moderna (MRNA)
Order type
Buy in
Order amount
Est. shares
0 shares